Article
Lab Invest 2001, 81:51–59
Variations of Proline-Rich Kinase Pyk2 Expression Correlate with Prostate Cancer Progression
This work was supported by grants from the Associazione Italiana Ricerca sul Cancro and from MURST/CNR "Biotecnologia."
Rosita Stanzione1,6, Antonietta Picascia1,2,6, Paolo Chieffi1, Ciro Imbimbo2, Alessandro Palmieri1,2, Vincenzo Mirone2, Stefania Staibano3, Renato Franco3, Gaetano De Rosa3, Joseph Schlessinger6 and Donatella Tramontano4,5
- 1Dipartimento di Biologia e Patologia Molecolare e Cellulare "Luigi Califano" and Centro di Endocrinologia ed Oncologia Sperimentale del CNR "Gaetano Salvatore", Benevento, Italy
- 2Clinica Urologica, Dipartimento di Scienze Biomorfologiche e Funzionali, Università degli Studi di Napoli "Federico II" Naples, Benevento, Italy
- 3Sezione di Patologia, Università degli Studi di Napoli "Federico II" Naples, Benevento, Italy
- 4Facoltà di Scienze, Università del Sannio, Benevento, Italy
- 5Dipartimento di Medicina Sperimentale e Clinica "Gaetano Salvatore", Università di Catanzaro "Magna Græcia," Catanzaro, Italy
- 6Department of Pharmacology, New York University Medical Center, New York City, New York
Correspondence: Dr. Donatella Tramontano, Dipartimento Biologia e Patologia Molecolare, e Cellulare "Luigi Califano," Via Pansini, 5 80131 Naples, Italy. E-mail: Tramontano@unisannio.it
6These authors contributed equally to this report: RS, AP.
Received 7 August 2000.
Abstract
Proline-rich kinase 2 (Pyk2), also known as CAK
(cell adhesion kinase
), is a cytoplasmic tyrosine kinase that is structurally related to focal adhesion kinase. Pyk2 is expressed in different cell types including brain cells, fibroblasts, platelets, and other hemopoietic cells. Pyk2 is rapidly tyrosine phosphorylated in response to diverse extracellular signals acting via different post receptor pathways. We have investigated whether this protein kinase is functionally expressed in normal and neoplastic prostate tissues. In this study, we demonstrate that Pyk2 is expressed only in normal epithelial prostate tissue and in benign prostatic hyperplasia, whereas its expression progressively declines with an increasing grade of malignancy of prostate cancer.

